直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Patent Trial and Appeal Board Canceled over 90% of Claims Decided in February and Often Relies on Extrinsic Evidence That May Be Entitled to Deference on Appeal

March 26, 2015

Authored and Edited by Daniel F. Klodowski; Aaron L. Parker

February was a particularly brutal month for patent owners before the Board. Considering only final written decisions, statistics show that the PTAB canceled over 90% of the IPR claims that reached Final Written Decision. Does this herald a greater trend, or just statistical anomaly?

PTAB-STATS---IPR-FWD-Results-by-Claim-2.15

To contrast, for all IPRs decided to date, the Board has canceled roughly 70% of instituted claims—over 2,500 claims. That doesn’t include claims in which the board does not institute IPR, claims in challenged patents in which the parties to the IPR settled their dispute, and claims that have been canceled by a request for adverse judgment, a related reexamination, or a final court judgment. It also (quite obviously) excludes claims not challenged. So the February anomaly may be just that—noise in the data—or it may signify better odds by savvy petitioners who go the distance.

Our analysis also reveals that the Board often relies on extrinsic evidence when supporting claim construction positions it takes in final written decisions—evidence like dictionaries, experts, party admissions, litigation materials, party admissions, and technical standards. To date, in more than 31% of final written decisions, the Board cites a dictionary in at least partial support for a claim construction position; they rely on expert testimony in more than 17% of final written decisions; and that they sometimes rely on other evidence outside of the specification to bolster their claim construction positions.

PTAB-STATS--Claim-Construction-Evidence-Used_3.15

This is all the more notable because in deciding In re Cuozzo Speed Technologies, LLC, No. 14-1301 (Fed. Cir. Feb. 4, 2015), the Federal Circuit held that the deferential “substantial evidence” standard applies to Board factual findings for claim construction, citing the Supreme Court’s recent decision in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 135 S. Ct. 831, 841 (2015).

As a result, Board decisions on appeal—particularly those hinging on claim construction—may be effectively protected from de novo review by the Federal Circuit, where the PTAB relies on extrinsic evidence to support its claim construction positions.

Tags

Final Written Decision

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Aaron L. Parker
Partner
Washington, DC
+1 202 408 4387
Email

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP